SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 185 filers reported holding SAGE THERAPEUTICS INC in Q3 2017. The put-call ratio across all filers is 1.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $3,000 | 0.0% | 19 | -44.1% | 0.00% | 0.0% |
| Q4 2018 | $3,000 | -40.0% | 34 | 0.0% | 0.00% | -50.0% |
| Q3 2018 | $5,000 | -16.7% | 34 | -15.0% | 0.00% | 0.0% |
| Q2 2018 | $6,000 | 0.0% | 40 | 0.0% | 0.00% | -33.3% |
| Q1 2018 | $6,000 | -66.7% | 40 | -62.3% | 0.00% | -62.5% |
| Q4 2017 | $18,000 | +157.1% | 106 | 0.0% | 0.01% | +166.7% |
| Q3 2017 | $7,000 | -22.2% | 106 | -1.9% | 0.00% | -40.0% |
| Q2 2017 | $9,000 | +12.5% | 108 | 0.0% | 0.01% | +25.0% |
| Q1 2017 | $8,000 | +33.3% | 108 | -3.6% | 0.00% | +33.3% |
| Q4 2016 | $6,000 | +20.0% | 112 | 0.0% | 0.00% | -25.0% |
| Q3 2016 | $5,000 | -16.7% | 112 | -35.6% | 0.00% | 0.0% |
| Q2 2016 | $6,000 | 0.0% | 174 | 0.0% | 0.00% | -20.0% |
| Q1 2016 | $6,000 | -25.0% | 174 | +43.8% | 0.01% | -16.7% |
| Q4 2015 | $8,000 | +100.0% | 121 | +37.5% | 0.01% | +100.0% |
| Q3 2015 | $4,000 | -42.9% | 88 | 0.0% | 0.00% | -40.0% |
| Q2 2015 | $7,000 | – | 88 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Casdin Capital, LLC | 312,000 | $29,886,000 | 5.11% |
| DAFNA Capital Management LLC | 104,306 | $9,991,000 | 4.97% |
| Palo Alto Investors LP | 850,977 | $81,515,000 | 4.34% |
| BB BIOTECH AG | 1,375,229 | $131,733,000 | 4.22% |
| Eventide Asset Management | 936,000 | $89,659,000 | 3.97% |
| TRV GP II, LLC | 37,362 | $3,579,000 | 3.56% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 146,179 | $14,002,000 | 2.11% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 111,908 | $10,720,000 | 2.06% |
| OAK RIDGE INVESTMENTS LLC | 231,483 | $22,174,000 | 1.60% |
| Rhenman & Partners Asset Management AB | 137,339 | $13,156,000 | 1.50% |